awmsg logo



alogliptin/metformin (Vipdomet®)


Reference No. 1271

Publication date:
31/10/2014


Appraisal information

alogliptin/metformin (Vipdomet®) 12.5 mg/1000 mg film-coated tablet


Company: Takeda UK Ltd
BNF category: Endocrine system
NMG meeting date: 10/09/2014
AWMSG meeting date: 08/10/2014
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 3314
Ministerial ratification: 30/10/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Alogliptin/metformin (Vipdomet®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin/metformin (Vipdomet®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • As an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin as separate tablets. Alogliptin/metformin (Vipdomet®) is not recommended for use within NHS Wales outside of these circumstances.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download